Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Work In Process (2024 - 2026)

PROCEPT BioRobotics has reported Work In Process over the past 3 years, most recently at $12.8 million for Q1 2026.

  • Quarterly Work In Process rose 17.75% to $12.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.8 million through Mar 2026, up 17.75% year-over-year, with the annual reading at $13.4 million for FY2025, 17.42% up from the prior year.
  • Work In Process was $12.8 million for Q1 2026 at PROCEPT BioRobotics, down from $13.4 million in the prior quarter.
  • Over five years, Work In Process peaked at $13.4 million in Q4 2025 and troughed at $10.9 million in Q1 2025.
  • The 3-year median for Work In Process is $12.8 million (2025), against an average of $12.4 million.
  • Year-over-year, Work In Process increased 17.42% in 2025 and then grew 17.75% in 2026.
  • A 3-year view of Work In Process shows it stood at $11.5 million in 2024, then increased by 17.42% to $13.4 million in 2025, then fell by 4.57% to $12.8 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Work In Process are $12.8 million (Q1 2026), $13.4 million (Q4 2025), and $12.8 million (Q3 2025).